|
Jun 1
|
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 29
|
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
|
|
Mar 7
|
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 12
|
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
|